Mobile App-Supported HPV and Breast Cancer Awareness Program
Phase NA Completed
70 enrolled
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Completed
377 enrolled
MiGHT
Phase NA Completed
831 enrolled
CATALYST
Phase NA Completed
50 enrolled
LYSA
Phase NA Completed
200 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
Phase NA Completed
1,330 enrolled
CONFIGURE
Phase NA Completed
41 enrolled 6 charts
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
Completed
40 enrolled
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase 1 Completed
40 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Phase 1 Completed
69 enrolled
AH-HA
Phase NA Completed
600 enrolled
BRIDGEScohort2
Phase NA Completed
405 enrolled
INOVOLINE
Phase NA Completed
101 enrolled
AYAConnect
Phase NA Completed
63 enrolled
Enhancing Cancer Prevention and Control Pathways-Native Health Initiative
Phase NA Completed
508 enrolled 8 charts
Study of ESG401 in Adults With Solid Tumors
Phase 1/2 Completed
156 enrolled
Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen
Phase NA Completed
60 enrolled
EARN
Phase NA Completed
33 enrolled
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
OLAP
Completed
661 enrolled
CNSI-Fe(II)
Phase 1 Completed
19 enrolled 47 charts
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 Completed
23 enrolled
PRIORITY
Completed
346 enrolled 9 charts
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Phase 1 Completed
285 enrolled
Doxil/Caelyx BE Study
Phase 1 Completed
36 enrolled
P-COC
Phase NA Completed
60 enrolled
GRACE
Phase NA Completed
668 enrolled 25 charts
Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer
Phase NA Completed
49 enrolled
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
Phase NA Completed
40 enrolled
Improved Early Diagnosis in Female Pelvic Cancer With OC Detect
Completed
490 enrolled
Genomic Testing and Resulting Medical Decisions
Completed
1,500 enrolled
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
Phase 1 Completed
66 enrolled
PREFER
Completed
1,429 enrolled
Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda
Completed
2,357 enrolled
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Phase 1 Completed
112 enrolled
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Phase NA Completed
128 enrolled 24 charts
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
Phase 1/2 Completed
323 enrolled
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Phase 1 Completed
26 enrolled
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Phase 1 Completed
121 enrolled
Southeast Asian Women's Health Project
Phase NA Completed
194 enrolled
MOVIE
Phase 1/2 Completed
126 enrolled
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Phase 1 Completed
10 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Phase 1 Completed
279 enrolled
Study of Continuous OSI-906 Dosing
Phase 1 Completed
95 enrolled
IVY
Phase 1 Completed
353 enrolled
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Phase 1 Completed
29 enrolled
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Phase 1 Completed
190 enrolled